Tech Company Financing Transactions
Ucello Therapeutics Funding Round
Ucello Therapeutics closed a $25 million Series A funding round on 2/23/2022. Investors included Matrix Partners, Chengdu International Bio-Town Investment and Development and Co-win Healthcare Fund.
Transaction Overview
Company Name
Announced On
2/23/2022
Transaction Type
Venture Equity
Amount
$25,000,000
Round
Series A
Investors
Proceeds Purpose
Proceeds from the financing will be used to advance the company's development of proprietary universal CAR-T technology platform CBT-X20, progress pipeline programs including lead asset AT19 through to US and China IND filings, and build a state of the art GMP-ready clinical manufacturing facilities.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
D1 Tianfu International Biological City Shuangliu District
Chengdu, Undisclosed
China
Chengdu, Undisclosed
China
Phone
Website
Email Address
Overview
Ucello Therapeutics is engaged in development of allogeneic cell therapies using its proprietary CAR-T cell technology platform CBT-X20.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Qiang Zou
Browse more venture capital transactions:
Prev: 2/23/2022: Duplo venture capital transaction
Next: 2/23/2022: Stable Insurance venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs